Novavax Announces Leadership Change
(Thomson Reuters ONE) -
GAITHERSBURG, Md., Oct. 13, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc.,
(Nasdaq:NVAX) announced today that Barclay A. "Buck" Phillips has submitted his
resignation as Senior Vice President, Chief Financial Officer (CFO) and
Treasurer, to pursue an expanded opportunity in the industry. Mr. Phillips will
step down effective November 10, 2017, and will provide financial, accounting
and transition services as a consultant to Novavax until December 31, 2017. Mr.
Erck will act as the interim CFO pending completion of a search for a new Chief
Financial Officer.
"Buck has been instrumental in a number of significant Novavax accomplishments,
and we thank him for all his contributions over the last four years. We wish him
all the best in his new endeavors," said Stanley C. Erck, President and CEO of
Novavax.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed
to delivering novel products to prevent a broad range of infectious diseases.
Our recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the
foundation for groundbreaking innovation that improves global health through
safe and effective vaccines. Additional information about Novavax is available
on the Company's website, novavax.com.
Contact:
Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Director, Investor & Media Relations
ir(at)novavax.com
240-268-2000
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.10.2017 - 13:30 Uhr
Sprache: Deutsch
News-ID 563621
Anzahl Zeichen: 2043
contact information:
Town:
Maryland
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 357 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novavax Announces Leadership Change"
steht unter der journalistisch-redaktionellen Verantwortung von
Novavax, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
